A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies

Cell Rep. 2024 Dec 24;43(12):115010. doi: 10.1016/j.celrep.2024.115010. Epub 2024 Dec 14.

Abstract

Antibodies that target the gp120-gp41 interface of the HIV-1 envelope (Env) trimer comprise a commonly elicited category of broadly neutralizing antibodies (bNAbs). Here, we isolate and characterize VRC44, a bNAb lineage with up to 52% neutralization breadth. The cryoelectron microscopy (cryo-EM) structure of antibody VRC44.01 in complex with the Env trimer reveals binding to the same gp120-gp41 interface site of vulnerability as antibody 35O22 from a different HIV-1-infected donor. In addition to having similar angles of approach and extensive contacts with glycans N88 and N625, VRC44 and 35O22 derive from the same IGHV1-18 gene and share convergent mutations, indicating these two antibodies to be members of the only known highly glycan-dependent multidonor class. Strikingly, both lineages achieved almost 100% neutralization breadth against virus strains displaying high-mannose glycans. The high breadth and reproducible elicitation of VRC44 and 35O22 lineages validate germline-based methods of immunogen design for targeting the HIV-1 gp120-gp41 interface.

Keywords: 35O22; CP: Immunology; CP: Molecular biology; HIV-1 envelope trimer; N90; broadly neutralizing antibody; glycan; multidonor antibody class; subunit interface.

MeSH terms

  • Antibodies, Neutralizing* / immunology
  • Broadly Neutralizing Antibodies / immunology
  • Cryoelectron Microscopy
  • HIV Antibodies / immunology
  • HIV Envelope Protein gp120* / immunology
  • HIV Envelope Protein gp120* / metabolism
  • HIV Envelope Protein gp41* / immunology
  • HIV Envelope Protein gp41* / metabolism
  • HIV-1* / immunology
  • Humans
  • Polysaccharides* / immunology
  • Polysaccharides* / metabolism

Substances

  • HIV Envelope Protein gp120
  • Polysaccharides
  • Antibodies, Neutralizing
  • HIV Envelope Protein gp41
  • HIV Antibodies
  • Broadly Neutralizing Antibodies